POPULARITY
51 episodes with obstructive
26 episodes with obstructive
15 episodes with obstructive
15 episodes with obstructive
6 episodes with obstructive
4 episodes with obstructive
7 episodes with obstructive
3 episodes with obstructive
2 episodes with obstructive
Every CRNA school interview panel asks about shock. Most applicants can name the four types. What separates the answers that land is mechanism — Frank-Starling in hypovolemic, the afterload trap in cardiogenic, iNOS-driven nitric oxide collapse in distributive, RV dilation and septal shift in obstructive. This episode covers all four shock states at the cellular level: hemodynamic profiles, bedside clues, and the exact language to use when a program asks you to walk through shock in an interview. We have a full shock states lesson inside The CRNA Club learning library — hemodynamic profiles for every shock type, built for CCRN prep and CRNA interview practice. Start your free seven-day trial. FREE RESOURCES TO HELP YOU ON YOUR CRNA JOURNEY: Transcript Analyzer - Find out if your GPA is competitive for CRNA school 9-Step Application Checklist - Every step you need to apply to CRNA school, in order CRNA School Database - Search and compare 140+ CRNA programs Certification Planner - Your personalized CCRN study schedule Timeline Generator - Build your personalized application timeline Try The CRNA Club FREE for 7 days - The only tool personalized to YOUR CRNA school journey CHAPTERS: [00:00] Cold open: warm post-op patient, ambiguous shock type [01:30] Welcome and shared framework: shock as inadequate tissue perfusion [02:30] Tank, pump, pipes, obstruction overview [03:00] Hypovolemic shock: Frank-Starling, sympathetic compensation, why pressors alone fail [06:00] Mid-episode: learning library shock lesson [07:00] Cardiogenic shock: calcium handling failure, the afterload trap, inotrope rationale [10:00] Distributive shock: iNOS, nitric oxide, why norepinephrine targets the right receptor [13:00] Obstructive shock: PE anatomy, tension pneumo, tamponade — and Beck's triad caveat [15:00] How to answer the shock question in your CRNA interview [16:30] Three clinical takeaways and cold open callback Follow us on Instagram: @thecrnaclub More resources at THECRNACLUB.COM
Dr Peter Wallbridge (sleep and respiratory physician) joins Dr Preeya again after multiple requests from the audience for another chat on sleep! Obstructive sleep apnea - why it can present differently in women, options for management and all the super interesting stuff everyone wants to know on dreaming, sleep walking and talking!Instagram: @doctor.preeya.alexanderBooks: Eat, Sleep, Play, Love by Dr Preeya AlexanderFull Plate, out nowTo find out more about AIA Australia head to www.aia.com.au
In this episode, we review the high-yield topic of Obstructive Shock from the Cardiovascular section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
In this episode, Dr Dave McCarty returns to discuss why sleep apnea is often misunderstood and oversimplified. He introduces his “Five Reasons to Treat” and “Five-Finger Approach” frameworks, helping patients and practitioners better understand the deeper causes of sleep-disordered breathing. The discussion explores: Obstructive vs central sleep apnea Nasal breathing and nitric oxide ADHD and sleep disorders Mouth breathing and facial development Narrative-based medicine The dangers of relying solely on labels Empowering patients through understanding This episode challenges conventional thinking and provides a more holistic, personalized way to approach sleep health. Dr Dave McCarty Dr Dave McCarty is a sleep physician, educator, writer, illustrator, and creator of the Empowered Sleep Apnea Project. He is known for making complex sleep science understandable through storytelling, cartoons, patient education, and narrative-based medicine. His work focuses on helping people understand sleep apnea beyond labels and empowering patients to become active participants in their healthcare journey. Website: Empowered Sleep Apnea Social Media: Dr Dave McCarty on LinkedIn Empowered Sleep Apnea YouTube Featured Books: The Nose Rules Empowered Sleep Apnea ✍️
Lisa Salberg and Dr. Marty Maron break down major new clinical trial results that could change treatment for patients with non obstructive HCM. They explain what the Acacia HCM trial found, why experts call it a transformative moment, and what the next steps could mean for patients around the world. This conversation was recorded May 5, 2026.
Valerie Dehondt, PharmD, and Lies Lahousse, PharmD, PhD, join CHEST® Journal Podcast Moderator Gretchen Winter, MD, to discuss their research into the association between long-term proton pump inhibitor use and exacerbation risk in patients with chronic obstructive airway diseases. DOI: 10.1016/j.chest.2026.01.002 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine.
Drs. Maron and Rowin review how treatment for symptomatic obstructive hypertrophic cardiomyopathy has evolved from mainly using beta blockers and invasive procedures to now including newer cardiac myosin inhibitor drugs. These newer medications more reliably reduce obstruction and improve patient symptoms and exercise capacity, but require careful safety monitoring with regular heart function checks.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.
Drs. Maron and Rowin provide an overview of hypertrophic cardiomyopathy, explaining how it is diagnosed by heart imaging and classified into obstructive and non-obstructive forms. They highlight that obstruction is a major cause of symptoms and stress the importance of carefully assessing patients' day-to-day limitations to guide treatment decisions.
CME credits: 1.00 Valid until: 26-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-beta-blockers-to-myosin-inhibitors-initial-decision-making-in-obstructive-hcm/54843/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/modern-obstructive-hcm-care-from-unmet-needs-to-individualized-myosin-inhibitor-therapy/56979/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.
Joe and Anthony get back together for an hor full of crazy news and filled with Joe's giggle machine.. How they get from here to there is anyone's guess, maybe you can figure it out, shows on Mondays, every other week at chiampa.org (otherwise it's a repeat of a previous cast)
In this episode of the Heart podcast, Digital Media Editor Professor James Rudd is joined by Dr Craig Balmforth from the University of Edinburgh. They discuss the rationale for identifying high-risk plaque, how imaging can help, and emerging therapies, including PCI. If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us to reach more people - thanks! Link to published paper: https://heart.bmj.com/content/112/1/13.long
Insomnia refers to the persistent difficulty with getting to sleep, maintaining sleep, or quality of sleep that occurs despite adequate opportunity and circumstances for sleep and results in impaired daytime functioning. It can often be a sign of an underlying psychological or physical condition.In this episode of the Clinical Update podcast, MIMS Learning editors Dawn and Pat review how insomnia should be assessed in primary care and how it should be managed. They also discuss related sleep disorders, such as obstructive sleep apnoea (OSA) and night sweats.Given sleep disorders can lead to sleep deprivation and daytime sleepiness, the editors also look at DVLA regulations on driving with a sleep disorder.Educational objectivesAfter listening to this podcast, healthcare professionals should be more able to:Discuss the types of insomniaRecall pharmacological options for treating insomniaReview the risk factors for OSAAppreciate the role of the GP in supporting patients with suspected OSAInvestigate the possible causes of night sweatsYou can access the website version of this podcast, along with a list of key learning points, on MIMS Learning - and make notes for your appraisal. MIMS Learning offers hundreds of hours of CPD for healthcare professionals, along with a handy CPD organiser.Please note: this podcast is presented by medical editors and discusses educational content written or presented by doctors, nurses and other healthcare professionals on the MIMS Learning website and at live events.MIMS LearningRegister for a free MIMS Learning accountAdult obstructive sleep apnoea syndrome: clinical reviewConfidence in Obesity CareInsomnia - red flag symptomsNight sweats - red flag symptoms Hosted on Acast. See acast.com/privacy for more information.
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
In this podcast accompanying the October issue of DTB (https://dtb.bmj.com/content/63/10) David Phizackerley (DTB Editor) is joined by Julian Treadwell (DTB Associate Editor). David and Julian discuss the editorial that highlights a few of the challenges associated with the introduction of an orphan medicine into clinical practice (https://dtb.bmj.com/content/63/10/146). They talk about a DTB Select article that summarises a randomised clinical trial that assessed the effect of allopurinol on cardiovascular outcomes in people with ischaemic heart disease who did not have gout (https://dtb.bmj.com/content/63/10/147). They finish by discussing the main article that provides an overview of the evidence for mavacamten (▼Camzyos) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults (https://dtb.bmj.com/content/63/10/150). Links GP Evidence: https://gpevidence.org/ Preventing Overdiagnosis 2025 International Conference: https://www.cebm.ox.ac.uk/preventing-overdiagnosis Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page. If you want to contact us please email dtb@bmj.com. Thank you for listening.
Obstructive sleep apnea affects a whopping 30 million Americans, yet millions remain undiagnosed or abandon CPAP therapy due to its discomfort and inconvenience. Recent innovations in oral appliance therapy, however, are opening up new possibilities for patients seeking safe, effective, and lasting solutions. With sleep apnea linked to virtually every chronic disease—from heart disease to diabetes—the stakes couldn't be higher.So, what if there were a way to actually remodel the airway and reduce dependence on CPAP altogether? Could a non-surgical, dental-based approach reshape the future of sleep apnea treatment?Welcome to I Don't Care. In the latest episode, host Dr. Kevin Stevenson speaks with R. Kirk Huntsman, Chairman and CEO of Vivos Therapeutics. Together, they explore how airway remodeling through oral appliances may offer patients an alternative to CPAP, why craniofacial development is so central to sleep disorders, and how innovations in treatment are changing lives across the country.In this episode, you'll learn:How Vivos Therapeutics' oral appliance technology works by repositioning and redeveloping the jaws to create wider, more functional airways.Why environmental, genetic, and lifestyle factors have led to narrower airways in modern populations—and how this contributes to the rise of sleep apnea.What patients can expect in terms of treatment timelines, insurance coverage, and long-term outcomes, including reducing or eliminating dependence on CPAP.R. Kirk Huntsman is a seasoned healthcare entrepreneur with over 35 years of experience founding and leading companies in dental practice management, medical devices, and healthcare services. He built and scaled Dental One, Inc. into a $70M business before its sale, and later co-led the merger that created DentalOne Partners, operating over 150 practices nationwide. Currently Chairman and CEO of Vivos Therapeutics, he focuses on strategic growth, capital acquisition, and innovative technologies to advance treatment for sleep and airway disorders.
Ischemia with No Obstructive Arteries (INOCA) in 2024 Guest: Claire Raphael, M.B.B.S., Ph.D. Host: Sharonne Hayes, M.D. INOCA is a common condition. It is an acronym that stands for ischemia with non-obstructive coronary artery disease. We discuss when to consider a diagnosis of INOCA, how to diagnose it and how to treat patients. Topics Discussed: What is INOCA? Who is at risk for INOCA? How do we manage INOCA? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.
Stephen Grootes speaks to Carol Paton, Editor-at-Large at Fin24, about South Africa’s obstructive stance at the WTO, which she calls embarrassing and clearly misguided. Stephen Grootes speaks to veteran broadcaster Neil Andrews about his remarkable journey from horse-racing commentary to becoming one of South Africa’s most beloved sports presenters, highlighting the passion, versatility, and humility that have defined his decades-long career. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape. Thank you for listening to a podcast from The Money Show Listen live Primedia+ weekdays from 18:00 and 20:00 (SA Time) to The Money Show with Stephen Grootes broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/7QpH0jY or find all the catch-up podcasts here https://buff.ly/PlhvUVe Subscribe to The Money Show Daily Newsletter and the Weekly Business Wrap here https://buff.ly/v5mfetc The Money Show is brought to you by Absa Follow us on social media 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/CapeTalk 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/Radio702 CapeTalk on YouTube: https://www.youtube.com/@See omnystudio.com/listener for privacy information.
AUA2025: John Duckett Memorial Lecture: Obstructive Bladder Disease: Molecular Insights and Therapeutic Opportunities Presenter: Rosalyn M. Adam, PhD
Commentary by Dr. Jian'an Wang.
Atypical sleep apnoea in women, often presenting as fatigue, insomnia or anxiety Why all pregnant women in their second trimester should be screened Loud snoring and hyperactivity in children are red flags for sleep apnoea Home sleep test access, Medicare criteria, and private options explained Supporting CPAP setup, troubleshooting and when to refer Host: Dr David Lim | Total Time: 41 mins Expert: Dr Alison Wimms, Director of Medical Affairs Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.
Commentary by Dr. Jian'an Wang.
Primary and Secondary Outcomes of the Women's Ischemia Trial to Reduce Events in Non-Obstructive Coronary Artery Disease
Obstructive sleep apnea (OSA) is an increasingly common diagnosis. Yet most behavioral health providers are unaware that they can play a role in both the assessment and treatment of OSA in their patients. Today we're joined by an expert in the subfield of sleep psychology, Dr. Phil Gehrman. He shares basic information about what OSA is, how providers can effectively screen for it, and how they can facilitate treatment for this dangerous condition. Despite what you might have heard before, Dr. Gehrman posits that behavioral health providers can play “a huge potential role that really is untapped.” Dr. Phil Gehrman is Professor of Psychology in the Department of Psychiatry of the University of Pennsylvania School of Medicine. He directs the Sleep, Neurobiology and Psychopathology lab at Penn. He has an active research program exploring the mechanisms and treatment of sleep and circadian dysregulation in the context of mental health disorders. Dr. Gehrman's clinical specialization is on the delivery of cognitive behavioral and chronotherapeutic interventions for insomnia, circadian rhythm disorders, and other sleep disorders. The overarching goal of his work is to advance the understanding of the links between sleep and mental illness through translational research that spans biology to therapeutics.Resources mentioned in this episode: STOP Screening tool for Obstructive Sleep Apnea: https://deploymentpsych.org/content/insomnia-toolsMotivational Interviewing for CPAP Adherence: Rapelli G, Pietrabissa G, Manzoni GM, Bastoni I, Scarpina F, Tovaglieri I, Perger E, Garbarino S, Fanari P, Lombardi C and Castelnuovo G (2021) Improving CPAP Adherence in Adults With Obstructive Sleep Apnea Syndrome: A Scoping Review of Motivational Interventions. Front. Psychol. 12:705364. doi: 10.3389/fpsyg.2021.705364Motivational Interviewing resources: https://deploymentpsych.org/Clinical-Skills-ResourcesSystematic desensitization: https://www.veterantraining.va.gov/insomnia/docs/PAP_Desensitization.pdfPractical for Your Practice voice mail: speakpipe.com/cdpp4pPractical for Your Practice email: cdp-podcast-ggg@usuhs.edu Calls-to-action: Incorporate the STOP into your practiceBecome familiar with behavioral and motivational approaches listed aboveConnect with your local sleep medicine clinicReach out to us via Speakpipe with your questions and commentsSubscribe to the Practical for Your Practice PodcastSubscribe to The Center for Deployment Psychology Monthly Email at https://deploymentpsych.org/CDP-MED-Opt-In
Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Investigating the Anrep Effect in Hypertrophic Obstructive Cardiomyopathy With Invasive Pressure-Volume Analysis.
Be alert to atypical symptoms, such as fatigue or reduced exercise tolerance, particularly in younger patients Serial Holter monitoring and attention to atrial ectopy burden can guide suspicion Wearables like the Apple Watch and Samsung Galaxy Watch are effective adjuncts for rhythm detection Early ablation may be appropriate, even in younger patients with a low CHA₂DS₂-VASc score, if they are symptomatic Collaboration between healthcare professionals and Electrophysiologists is essential to optimise patient outcomes The questions answered in this podcast are listed below.They were compiled by GPs and health professionals around Australia who attended Healthed’s face-to-face seminars. Atrial fibrillation – it's not an uncommon arrhythmia in Australia, is it? What are some of the environmental factors that have been identified as contributing to atrial fibrillation, apart from COVID? Why are we picking up more cases of atrial fibrillation? Are patients becoming more symptomatic? Obstructive sleep apnoea doesn't cause atrial fibrillation, but can it make it permanent? How can the pulmonary veins cause a cardiac arrhythmia? What are the indications for treating patients with ablation? How is it managed? What's the current thinking? How far should a healthcare professionals go in trying to detect atrial fibrillation in patients with unusual symptoms? Host: David Lim | Total Time: 32 mins Expert: Prof Rukshen Weerasooriya, Sub-specialist Cardiac Electrophysiologist Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.
In this special episode on Obstructive Sleep Apnea our host, Dr. Neil Skolnik will discuss an overview of OSA. In Part 2 we will take a deep dive into diagnosis, Part 3 will discuss treatment options, and Part 4 will look at cases. This special episode is supported by an independent educational grant from Lilly. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Paul Doghramji, MD – Medical Director of Health Services at Ursinus College, Attending Family Physician at Collegeville Family Practice Selected references: Diagnosis and Management of Obstructive Sleep Apnea - A Review. JAMA. 2020;323(14):1389-1400 Obstructive sleep apnea and obesity: A review of epidemiology, pathophysiology and the effect of weight-loss treatments. Sleep Medicine Reviews 2024;78:1-12
In this Healthed lecture, Prof Brendon Yee explains how GPs and specialists can work together to ensure effective management, balancing road safety with appropriate return-to-driving protocols after successful treatment.See omnystudio.com/listener for privacy information.
Story at-a-glance Obstructive sleep apnea (OSA) affects nearly a billion people worldwide. It causes breathing interruptions during sleep that prevent you from reaching restorative sleep stages Common symptoms include loud snoring, gasping/choking during sleep, morning headaches, daytime fatigue, difficulty concentrating and mood changes that are often mistaken for normal tiredness Risk factors for OSA include age, excess throat tissue, weak throat muscles, structural airway abnormalities and vitamin D deficiency, which affects sleep regulation and quality Untreated sleep apnea leads to serious health complications including cardiovascular disease, Type 2 diabetes, cognitive decline, weakened immune function and increased accident risk Treatment options include CPAP therapy, oral appliances, orofacial myofunctional therapy and lifestyle changes like optimizing breathing habits, maintaining healthy weight and adjusting sleep position
In today's VETgirl online veterinary continuing education podcast, we discuss a potential way to help smooth out surgical recovery in those tricky brachycephalic patients. Listen along to hear the benefits one study found in having owners present to help recover their canine companion following airway surgery, as supported in the veterinary journal article, "Owner-assisted Recovery and Early Discharge After Surgical Treatment in Dogs with Brachycephalic Obstructive Airway Syndrome."
In today's VETgirl online veterinary continuing education podcast, Dr. Amy Kaplan, cVMA, DACVECC, MRCVS discusses a potential way to help smooth out surgical recovery in those tricky brachycephalic patients. Listen along to hear the benefits one study found in having owners present to help recover their canine companion following airway surgery, as supported in the veterinary journal article, "Owner-assisted Recovery and Early Discharge After Surgical Treatment in Dogs with Brachycephalic Obstructive Airway Syndrome."
This episode covers hypertrophic obstructive cardiomyopathy.Written notes can be found at https://zerotofinals.com/paediatrics/cardiology/hypertrophicobstructivecardiomyopathy/Questions can be found at https://members.zerotofinals.com/Books can be found at https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.
Sleep apnea is a sleep disorder characterized by repeated interruptions in breathing during sleep. Obstructive sleep apnea (OSA) is the most common type of sleep apnea, characterized by repeated episodes of partial or complete blockage of the airway during sleep. These blockages occur when the muscles at the back of the throat relax excessively, causing the airway to narrow or close, and momentarily stopping breathing. This condition contrasts with central sleep apnea, where the brain fails to send proper signals to the muscles that control breathing. When the brain is deprived of oxygen during sleep, OSA can lead to a number of serious conditions affecting not only quality of life, but brain health and function. It is important to seek medical attention.Omid B. Mehdizadeh, MD, is an otolaryngology-head & neck (ENT) surgeon with particular expertise in voice, swallowing and airway conditions at Pacific Neuroscience Institute (PNI). A Los Angeles native, his career has spanned treating world-class opera and Broadway singers to surgical mission trips serving underprivileged and indigenous populations of Central America. Outside PNI, he has focused his time on educating medical and undergraduate students and providing medical care to disenfranchised populations through community clinics.
Au lendemain d'une émission consacrée aux conseils et prises en charge pour cesser de fumer, nous parlons aujourd'hui d'une maladie chronique directement liée — dans une majorité de cas — à cette exposition au tabac. À l'occasion de la journée mondiale contre la BPCO (le 21 novembre), nous faisons un point sur cette maladie chronique inflammatoire des bronches. La bronchopneumopathie chronique obstructive (BPCO) est causée, dans environ 80% des cas, par la consommation de tabac, mais aussi par l'exposition à la biomasse, c'est-à-dire l'inhalation de fumées de combustion intérieure principalement, dans les Pays en Voie de Développement. Quels sont les symptômes de la BPCO ? Quelles prises en charge existent, pour les patients ? Pr Bruno CRESTANI, chef de service de pneumologie à l'hôpital Bichat Claude-Bernard à Paris. Président de la Fondation du Souffle Pr Alexandre Boko KOUASSI, pneumologue et responsable de l'unité d'aide au sevrage tabagique au CHU de Cocody en Côte d'Ivoire Christiane Poculu, patiente atteinte de BPCO, sous oxygénothérapie. Patiente experte diplômée de la faculté de médecine de l'université de Marseille. Vice-présidente de l'association « Santé respiratoire France ». Vice-présidente de l'Alliance contre le tabac Programmation musicale :► Seckou Keita – Bodula► Liniker – Negona dos olhos terriveis
Millions of people struggle with sleep, but letting a real condition go undiagnosed could be fatal. Obstructive sleep apnea occurs when the airway is blocked during sleep and can cause major issues, including your alertness during the day and mental health. Our experts discuss which treatment options may be right for you. Learn More: https://radiohealthjournal.org/i-accidentally-fell-asleep-at-the-wheel-the-dangers-of-sleep-apnea Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode, Dr. Valentin Fuster highlights the Forest HCM study, which focuses on the withdrawal of standard care medications in patients with obstructive hypertrophic cardiomyopathy receiving afficantin. The study shows promising results: nearly half of the patients who attempted to reduce or stop their medications did so successfully, with significant improvements in functional class and symptoms. While the findings suggest that afficantin may allow for the reduction of traditional therapies, caution is advised, as not all patients may benefit equally.
In this episode, Dr. Valentin Fuster introduces a dedicated focus on hypertrophic cardiomyopathy, featuring a pivotal study by Dr. Martin Maron and Dr. lacopo Olivotto on the impact of aficamptin. This pre-specified sub-analysis from the SEQUOIA HCM trial aims to comprehensively evaluate the drug's effects on various aspects of disease burden, enhancing our understanding of its clinical efficacy.
In this episode, Dr. Valentin Fuster delves into a groundbreaking study on the effects of the cardiac myosin inhibitor, Aficamten, on patients with obstructive hypertrophic cardiomyopathy. The findings reveal significant improvements in echocardiographic measures of cardiac function, despite a mild and reversible decrease in left ventricular ejection fraction, highlighting the need for long-term safety evaluations of this promising treatment.
In this episode, Dr. Valentin Fuster explores groundbreaking research on hypertrophic cardiomyopathy, focusing on the effects of the drug aficamten on cardiac structure and function. Highlighting significant findings from the Sequoia HCM trial, the discussion underscores the potential of aficamten to induce favorable cardiac remodeling and improve patient outcomes, signaling a transformative era in the management of this condition.
In this episode, Dr. Valentin Fuster delves into the latest research on hypertrophic cardiomyopathy, highlighting the significant health status improvements achieved with the new cardiac myosin inhibitor, Aficamten, compared to placebo. The findings from the Sequoia HCM study reveal that Aficamten markedly enhances patients' quality of life and alleviates symptoms like chest pain and shortness of breath, paving the way for more effective treatments in this challenging condition.
This week I'm talking to Dr Jane Ladlow. Jane is a veterinary surgeon who is widely known as an expert on BOAS, or brachycephalic obstructive airway syndrome. BOAS is the umbrella disorder that covers a variety of different airflow obstructions in different flat-faced breeds such as the pug, French bulldog, and English bulldog. Jane developed the Respiratory Function Grading Scheme, a straightforward clinical exam which allows grading of a BOAS-effected dog. Jane works with the Kennel Club in the UK to promote this scheme, which is also being rolled out in other countries including the US. I was really pleased to get to talk to Jane about BOAS, her grading scheme, and what this means for breeding healthy brachycephalic dogs.
Obstructive sleep apnea in adults (1:40), e-cigarettes (5:30), breastfeeding support for healthy mothers and infants (7:40), hematologic emergencies (10:20), midodrine for recurrent vasovagal syncope (15:30), and cranberry products for preventing urinary tract infections (17:20).
CardioNerds Dr. Josh Saef and Dr. Tommy Das join Dr. Omkar Betageri, Dr. Andrew Geissler, Dr. Philip Lacombe, and Dr. Cashel O'Brien from the Maine Medical Center in Portland, Maine to enjoy an afternoon by the famous Portland headlight. They discuss a case of a patient who presents with obstructive cardiogenic shock. Dr. Bram Geller and Dr. Jon Donnelly provide the Expert CardioNerd Perspectives & Review segment for this episode. Dr. Maxwell Afari, the Maine Medical Center cardiology fellowship program director highlights the fellowship program. Audio editing by CardioNerds Academy Intern, student doctor Tina Reddy. This is the case of a 42 year-old woman born with complicated Tetralogy of Fallot repair culminating in a 29mm Edwards Sapiens (ES) S3 valve placement within a pulmonary homograft for graft failure who was admitted to the cardiac ICU for progressive cardiogenic shock requiring vasopressors and inotropic support. Initial workup showed lactic acidosis, acute kidney injury, elevated NT-proBNP, and negative blood cultures. TTE showed at least moderate biventricular systolic dysfunction. She was placed on furosemide infusion, blood cultures were drawn and empiric antibiotics initiated. Right heart catheterization demonstrated elevated right sided filling pressures, blunted PA pressures with low PCWP, low cardiac index, and low pulmonary artery pulsatility index. Intracardiac echocardiography (ICE) showed a large mass within the ES valve apparatus causing restrictive valve motion with a low gradient across the pulmonic valve in the setting of poor RV function. Angiography revealed a large filling defect and balloon valvuloplasty was performed with immediate hemodynamic improvement. Blood cultures remained negative, she was gradually weaned off of inotropic and vasopressor support, and discharged. Despite empiric treatment for culture negative endocarditis and ongoing anticoagulation, she was readmitted for recurrent shock one month later at which time the pulmonic mass was revisualized on ICE. A valve-in-valve transcatheter pulmonary valve (29mm ES S3) was placed to compress what was likely pannus, with an excellent hemodynamic result and no visible mass on ICE. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media Pearls - Obstructive Cardiogenic ShocK Tetralogy of Fallot is the most common cyanotic defect and can lead to long term complications after surgical repair including chronic pulmonary insufficiency, RV dysfunction, residual RVOT obstruction and branch pulmonary artery stenoses. Chronic RV failure may be more indicative of a structural defect and therefore require interventional or surgical management. Valve thrombosis, infective endocarditis and obstructive pannus formation should be considered in the differential of a patient with obstructive shock with a prosthetic valve. Bioprosthetic pulmonic valve obstruction may be effectively managed with balloon valvuloplasty in patients who present in acute extremis but TCPV will likely provide a more lasting result. While valvular gradients are typically assessed via echocardiography, invasive hemodynamics can serve as a critical adjunctive tool in its characterization. Show Notes - Obstructive Cardiogenic ShocK Notes were drafted by Drs. Omkar Betageri, Philip Lacombe, Cashel O'Brien, and Andrew Geissler. What are the common therapies and management for Tetralogy of Fallot? Tetralogy of Fallot is the most common cyanotic defect in children beyond the age of one year Anatomic Abnormalities: Anterior and Superior deviation of the conal septum creating a SubAo VSD and encroachment on the RVOT.
Obstructive shock may be the least common type of shock, but it's no less critical. As part of Nurse PodCrawl 2024, Bryan Boling and Brandon Oto from the Critical Care Scenarios podcast join host Sarah Lorenzini in this episode to talk about the critical care management of obstructive shock. Together, they walk nurses through a patient scenario, detailing the diagnostic process of obstructive shock due to pulmonary embolism.Sarah, Bryan and Brandon review the three main causes of obstructive shock: pulmonary embolism, tension pneumothorax, and cardiac tamponade. They also discuss the importance of clinical assessments and diagnostic tools like ultrasound to distinguish between each cause, as well as considerations for treatment.This episode is the perfect resource for nurses who want to deepen their understanding of obstructive shock. Tune in now to hear insights from three experienced pros!Topics discussed in this episode:Patient assessment and key diagnostic toolsDiagnosing obstructive shock due to pulmonary embolismTreating obstructive shock due to pulmonary embolismTreatment implications for major causes of obstructive shockDiagnosis and treatment of tension pneumothoraxTreatment strategies for cardiac tamponadeKey takeaways on obstructive shock managementCheck out the rest of Nurse PodCrawl 2024 episodes around cardiogenic, hypovolemic, and distributive shock!Critical Care Scenarios: https://podcasts.apple.com/us/podcast/critical-care-scenarios/id1491559787How Not to Kill Your Patient: https://podcasts.apple.com/us/podcast/how-not-to-kill-your-patient/id1612099061Nurse Dose Podcast: https://podcasts.apple.com/us/podcast/nurse-dose-podcast/id1486427611The Q Word Podcast: https://podcasts.apple.com/us/podcast/the-q-word-podcast/id1407523803Straight A Nursing: https://podcasts.apple.com/us/podcast/straight-a-nursing-study-for-nursing-school-exams-nclex/id1210975738Up My Nursing Game: https://podcasts.apple.com/us/podcast/up-my-nursing-game/id1527032817Mentioned in this episode:Nurse's Week 2024 SpecialHAPPY NURSE'S WEEK! You can use code: NURSESWEEK2024 When you check out to get 50% off your first month of Rapid Response AcademyRapid Response and Rescue Intro CourseCONNECT
© 2020-2026 Ivy Podcast Discovery LLC
